“Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial”, J of Skin, vol. 3, p. S14, Nov. 2019, doi: 10.25251/skin.3.supp.14.